Dr. Derek Stuart Welsbie, MD, PhD

Dr. Welsbie practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Welsbie's NPI, 1588869945, was assigned on June 17, 2007. Dr. Welsbie graduated from David Geffen School of Medicine at UCLA in 2006. Dr. Welsbie's Maryland license number on file is D70539.

Dr. Welsbie's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Welsbie's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Welsbie is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Welsbie to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Welsbie practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Welsbie's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Welsbie is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Welsbie's licenses on file in 2 states: Maryland and California.

Dmand AI lists cataract, dry eye, glaucoma, glaucoma surgery and inflammation of iris among the conditions Dr. Welsbie treats.

CMS data shows 619 Medicare services from Dr. Welsbie across 4 procedure codes in 2024, for 298 Medicare patients. Medicare paid $52,639 for them. Every service was in an office.

CMS counts 298 Medicare patients who saw Dr. Welsbie in 2024. The largest group is 75 to 84, with 134 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 13% are also on Medicaid. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Welsbie's median patient age at 69, with 55% women.

In 2024, Dr. Welsbie wrote 617 Medicare Part D claims for 156 patients. 52% of them were for generic drugs. CMS names the drug for 565 of them, across 10 drugs with 11 or more claims each, at $62,883 in total drug cost. In 2023, CMS named 656 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Welsbie for performance year 2024, reported as part of a group. Dr. Welsbie accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 28 papers to Dr. Welsbie, published from 2009 to 2025. 2022 was the busiest year, with 4. The most frequent topics are Retinal Ganglion Cells, Disease Models, Animal and Glaucoma. Dr. Welsbie has published most often in Exp Eye Res. Dr. Welsbie's most frequent co-authors are Robert N. Weinreb, MD, Jiun Lap Do, MD, PhD and Andrew S. Camp, MD.

CMS Open Payments shows 21 general payments to Dr. Welsbie from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 41% of the total. Teva Pharmaceuticals USA, Inc. paid the most, $1,601.

Dmand AI lists 1 award for Dr. Welsbie, most recently CMS Stage 1 EHR in 2013.

Dr. Welsbie graduated from David Geffen School of Medicine at UCLA in 2006.

Dr. Welsbie is in network with 15 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.